| Literature DB >> 29891526 |
Christopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, Murad Alam, James S Andersen, Rachel Blitzblau, Glen M Bowen, Carlo M Contreras, Gregory A Daniels, Roy Decker, Jeffrey M Farma, Kris Fisher, Brian Gastman, Karthik Ghosh, Roy C Grekin, Kenneth Grossman, Alan L Ho, Karl D Lewis, Manisha Loss, Daniel D Lydiatt, Jane Messina, Kishwer S Nehal, Paul Nghiem, Igor Puzanov, Chrysalyne D Schmults, Ashok R Shaha, Valencia Thomas, Yaohui G Xu, John A Zic, Karin G Hoffmann, Anita M Engh.
Abstract
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.Entities:
Mesh：
Year: 2018 PMID： 29891526 PMCID： PMC9440150 DOI： 10.6004/jnccn.2018.0055
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 12.693